肿瘤防治研究2026，Vol.53Issue(7)：542-548,7.DOI:10.3971/j.issn.1000-8578.2026.25.0718
放疗联合脂质体伊立替康、卡瑞利珠单抗及抗血管生成治疗对晚期骨与软组织肉瘤的疗效与安全性:CAP研究的亚组分析
Efficacy and Safety of Radiotherapy Combined with Liposomal Irinotecan,Camrelizumab,and Anti-angiogenic Therapy in Advanced Bone and Soft Tissue Sarcoma:A Retrospective Subgroup Analysis of CAP Study
王婉如 1葛雨辰 2王晓露 2刘娟 2曹越 3刘宝瑞 2沈洁 2李茹恬1
作者信息
- 1. 210008 南京,南京中医药大学,鼓楼临床医学院,南京鼓楼医院肿瘤科||210008 南京,南京大学医学院附属鼓楼医院肿瘤中心暨南京大学临床肿瘤学研究所
- 2. 210008 南京,南京大学医学院附属鼓楼医院肿瘤中心暨南京大学临床肿瘤学研究所
- 3. 210008 南京,南京大学医学院
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of a combination therapy regimen comprising stereotactic body radiation therapy(SBRT)combined with liposomal irinotecan,camrelizumab,and anti-angiogenic therapy(CAP)in patients with advanced bone and soft tissue sarcomas.Methods This study is a prospective subgroup analysis of the multicenter,open-label,single-arm phase Ⅱ CAP trial(NCT04569916),which enrolled 60 patients with advanced solid tumors who had progressed after standard therapy between November 2020 and February 2023,including 11 patients with advanced bone and soft tissue sarcomas.All patients received sequential liposomal irinotecan within 48 hours after stereotactic body radiotherapy(SBRT),followed by maintenance therapy with camrelizumab and an anti-angiogenic agent until disease progression or intolerable toxicity.The primary efficacy endpoint was objective response rate(ORR).Secondary endpoints included disease control rate(DCR),progression-free survival(PFS),overall survival(OS),and safety.Results In the bone and soft tissue sarcoma subgroup(n=11),three patients achieved partial response(PR),five had stable disease(SD),and three experienced disease progression(PD).ORR was 27.3%,and DCR was 72.7%.mPFS was 5.8 months(95%CI:2.2-10.3),and mOS not reached.Regarding safety,adverse reactions primarily included bone marrow suppression,fatigue,and gastrointestinal reactions,indicating overall manageable toxicity.Conclusion As a subgroup analysis of the CAP study,this research suggests that radiotherapy combined with liposomal irinotecan,camrelizumab,and anti-angiogenic therapy demonstrates certain efficacy in advanced bone and soft tissue sarcomas that have failed multiple lines of treatment,with overall manageable adverse reactions.Future studies should expand the sample size.关键词
骨与软组织肉瘤/放疗/脂质体伊立替康/卡瑞利珠单抗/抗血管生成治疗Key words
Bone and soft tissue sarcoma/Radiotherapy/Liposomal irinotecan/Camrelizumab/Anti-angiogenic therapy分类
医药卫生引用本文复制引用
王婉如,葛雨辰,王晓露,刘娟,曹越,刘宝瑞,沈洁,李茹恬..放疗联合脂质体伊立替康、卡瑞利珠单抗及抗血管生成治疗对晚期骨与软组织肉瘤的疗效与安全性:CAP研究的亚组分析[J].肿瘤防治研究,2026,53(7):542-548,7.
